Skip to search formSkip to main contentSkip to account menu

IMMU-106

Known as: monoclonal antibody IMMU-106 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

veltuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results
8032 Background: An open-label, multicenter study has shown that the humanized anti-CD20 antibody, IMMU-106 (hA20), which has… 
2007
2007
Hapten-Peptide Induces Apoptosis in Human Non ^ Hodgkin Lymphoma Cell Lines Targeted by Anti-CD 20 Anti-Hapten Bispecific Antibodies
Purpose:Bispecific antibody (bsMAb) pretargeting procedures use divalent hapten-peptides to stabilize the binding of the hapten… 
2007
2007
Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma
2006
2006
Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.
7530 Background: The humanized anti-CD20 antibody, IMMU-106 (hA20), has similar murine CDRs to rituximab, but the remaining… 
2006
2006
A new method of constructing CD20/CD22 bispecfic antibody fusion proteins with improved direct lymphoma cytotoxicity compared to rituximab.
2536 Background: Anti-CD20 and anti-CD22 monoclonal antibodies (MAbs) have been shown to have antitumor activity in non-Hodgkin's… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)